Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues

Dr. Reddy's Laboratories (RDY) reported Q1 fiscal 2026 earnings of $0.20 per ADS and revenues of $997 million, both exceeding consensus estimates, driven by 11% year-over-year revenue growth largely from Global Generics, which rose 10%. However, North American generics declined 11% due to price erosion, contributing to a 350 basis point gross margin contraction. Strategically, RDY announced a global collaboration with Alvotech to co-develop a biosimilar to Merck's blockbuster Keytruda, a high-value move building on their existing partnership for an Amgen biosimilar, though the company currently carries a Zacks Rank #4 (Sell).

Analysis

Dr. Reddy's Laboratories (RDY) delivered a robust first-quarter fiscal 2026 performance, exceeding consensus estimates with earnings of $0.20 per ADS and revenues of $997 million. The 11% year-over-year revenue growth was primarily driven by a 10% increase in its Global Generics segment, bolstered by a nicotine therapy acquisition in Europe and strong branded market performance. However, this positive top-line result is contrasted by significant underlying challenges. The crucial North America segment experienced an 11% revenue decline due to intensified price erosion on key products, which directly contributed to a 350 basis point contraction in gross margin to 56.9%. Concurrently, SG&A expenses rose 13% as the company increased investments. Strategically, RDY is positioning for future growth through high-value biosimilars, evidenced by a new global agreement with Alvotech to co-develop a biosimilar for Merck's blockbuster drug, Keytruda. This builds upon an existing partnership for an Amgen biosimilar, which is now under FDA review, signaling a clear long-term strategy to tap into major biologic revenue streams. Despite the stock's relative outperformance year-to-date, declining 7.5% against the industry's 11.4% drop, the combination of margin pressure and a Zacks Rank #4 (Sell) indicates that near-term operational headwinds are a key concern.

Key Decisions for Investors

• Investors should weigh the positive top-line beat and strategic biosimilar pipeline potential against the significant gross margin contraction and persistent price erosion in the North American generics market.
• The collaboration with Alvotech for a Keytruda biosimilar presents a substantial long-term growth catalyst, but its financial impact is several years away and subject to clinical and regulatory success.
• Given the conflicting signals of a strong earnings report against a Zacks #4 (Sell) rating and declining margins, it may be prudent to monitor for stabilization in North American pricing and further progress in the biosimilar pipeline before increasing exposure.